ITCI Intra-Cellular Therapies Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ITCI

Price (delayed)

$80.39

Market cap

$8.49B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$8.36B

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this ...

Highlights
The gross profit has soared by 66% YoY and by 11% from the previous quarter
The revenue has soared by 65% YoY and by 11% from the previous quarter
ITCI's quick ratio is down by 42% YoY and by 9% from the previous quarter
The equity has declined by 4.5% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.intracellulartherapies.com
Peers: CRIS MNOV LGND XNCR

Key stats

What are the main financial stats of ITCI
Market
Shares outstanding
105.57M
Market cap
$8.49B
Enterprise value
$8.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.98
Price to sales (P/S)
15.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.27
Earnings
Revenue
$513.93M
EBIT
-$109.88M
EBITDA
-$109.36M
Free cash flow
-$98.52M
Per share
EPS
-$1.16
Free cash flow per share
-$1.02
Book value per share
$6.19
Revenue per share
$5.31
TBVPS
$7.71
Balance sheet
Total assets
$747.04M
Total liabilities
$147.54M
Debt
$16.38M
Equity
$599.5M
Working capital
$555.73M
Liquidity
Debt to equity
0.03
Current ratio
5.12
Quick ratio
4.51
Net debt/EBITDA
1.14
Margins
EBITDA margin
-21.3%
Gross margin
92.8%
Net margin
-21.6%
Operating margin
-25.7%
Efficiency
Return on assets
-15.3%
Return on equity
-18.5%
Return on invested capital
-22.1%
Return on capital employed
-17.9%
Return on sales
-21.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITCI stock price

How has the Intra-Cellular Therapies stock price performed over time
Intraday
-0.56%
1 week
7.39%
1 month
13.08%
1 year
31.04%
YTD
12.25%
QTD
17.37%

Financial performance

How have Intra-Cellular Therapies's revenue and profit performed over time
Revenue
$513.93M
Gross profit
$477.04M
Operating income
-$131.94M
Net income
-$110.87M
Gross margin
92.8%
Net margin
-21.6%
The net margin has surged by 71% year-on-year and by 28% since the previous quarter
The operating margin has soared by 67% YoY and by 25% from the previous quarter
The gross profit has soared by 66% YoY and by 11% from the previous quarter
The revenue has soared by 65% YoY and by 11% from the previous quarter

Growth

What is Intra-Cellular Therapies's growth rate over time

Valuation

What is Intra-Cellular Therapies stock price valuation
P/E
N/A
P/B
12.98
P/S
15.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.27
The EPS has soared by 52% YoY and by 21% from the previous quarter
ITCI's P/B is 91% above its 5-year quarterly average of 6.8 and 26% above its last 4 quarters average of 10.3
The equity has declined by 4.5% year-on-year
The stock's price to sales (P/S) is 99% less than its 5-year quarterly average of 1854.3 but 7% more than its last 4 quarters average of 14.1
The revenue has soared by 65% YoY and by 11% from the previous quarter

Efficiency

How efficient is Intra-Cellular Therapies business performance
The ROS has soared by 71% YoY and by 28% from the previous quarter
Intra-Cellular Therapies's ROA has increased by 48% YoY and by 21% from the previous quarter
The ROE has grown by 45% YoY and by 20% from the previous quarter
ITCI's return on invested capital is up by 42% year-on-year and by 17% since the previous quarter

Dividends

What is ITCI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITCI.

Financial health

How did Intra-Cellular Therapies financials performed over time
The total liabilities has soared by 56% YoY and by 8% from the previous quarter
The company's current ratio fell by 42% YoY and by 5% QoQ
The debt is 97% smaller than the equity
The debt has declined by 11% year-on-year and by 3.3% since the previous quarter
The equity has declined by 4.5% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.